JinHuangJieDu for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
JinHuangJieDu may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed JinHuangJieDu in detail.
, JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation, Frontiers in Medicine, doi:10.3389/fmed.2026.1817137
Background Since the emergence and spread of coronavirus disease 2019 (COVID-19), Traditional Chinese Medicine (TCM) and its formulations have been used extensively in China for preventing and treating COVID-19 with demonstrated clinical efficacy. This study aimed to evaluate both the therapeutic potential and the mechanism of action of a newly designed TCM formula, JinHuangJieDu (JHJD), which is composed of Lonicerae Japonicae Flos , Scutellariae Radix, Pogostemonis Herba , Angelicae Dahuricae Radix , Taraxaci Herba , and Menthae Haplocalycis Herba . Methods The inhibitory effects of JHJD on SARS-CoV-2 spike RBD binding to ACE2 and pseudovirus infection were assessed in vitro . Network pharmacology analyses predicted JHJD’s active ingredients, target genes, and enriched pathways. Key targets were validated in vitro for their role in mitigating virus-induced inflammation. Results JHJD effectively blocked wildtype and Omicron RBD binding to ACE2 and inhibited pseudovirus infection. Network analyses identified 375 ingredients, 338 targets (primarily in lung, stomach and spleen), and 63 significant pathways related to viral infection/inflammation. Intersectional analysis suggested CCND1 and HIF1A as pivotal genes and in vitr o validation confirmed that JHJD targets HIF-1α to attenuate inflammation. Conclusion JHJD, a de novo designed TCM formula, effectively inhibits SARS-CoV-2 entry with superior efficacy against Omicron sub-variants. The formulation has a dual mode of action including disruption of the RBD–ACE2 interaction and alleviation of virus-induced inflammation by modulating HIF-1α. These dual mechanisms establish JHJD as a promising therapeutic candidate for COVID-19.